Azaaromatic amide derivatives for the treatment of cancer

A compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein
• Y is selected from C, N, C—CF3, and C—Cl;
• G is selected from aryl, heteroaryl, or heterocyclyl, preferably C6-10 aryl, C5-10 heteroaryl, or C4-10 heterocyclyl, and wherein the aryl, heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, oxo, halogen, or C1-6 haloalkyl;
• R1 is selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl, or C1-6 haloalkoxy;
• R2 is selected from C1-6 alkyl, C1-6 heteroalkyl, C6-10 aryl, C5-10 heteroaryl, C4-10 heterocyclyl, C6-10 aryl-C1-6 alkylene, C5-10 heteroaryl-C1-6 alkylene, or C4-10 heterocyclyl-C1-6 alkylene, wherein the alkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl;
• R3 is selected from hydrogen or C1-6 alkyl;
• or R2 and R3 together with the nitrogen atom to which they are attached form a heteroaryl or heterocyclyl, preferably a C3-10 heterocyclyl, wherein the heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl;
• R4 is selected from hydrogen or C1-6 alkyl;
• R5 is selected from the following groups:

A compound of formula (II) or a pharmaceutically acceptable salt thereof:

• wherein
• Y is selected from C, N, C—CF3, and C—Cl;
• X is selected from C and N;
• G is selected from aryl, heteroaryl or heterocyclyl, preferably C6-10 aryl, C5-10 heteroaryl, or C4-10 heterocyclyl, and wherein the aryl, heteroaryl, or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, oxo, halogen, C6-C10 aryl, C5-10 heteroaryl or C4-10 heterocyclyl, C1-6 haloalkyl or C1-C6 aminoalkyl;
• R1 is selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl, or C1-6 haloalkoxy;
• R2 is selected from C1-6 alkyl, C1-6 heteroalkyl, C6-10 aryl, C5-10 heteroaryl, C4-10 heterocyclyl, C6-10 aryl-C1-6 alkylene, C5-10 heteroaryl-C1-6 alkylene, or C4-10 heterocyclyl-C1-6 alkylene, wherein the alkyl, aryl, heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl;
• R3 is selected from hydrogen or C1-6 alkyl;
• or R2 and R3 together with the nitrogen atom to which they are attached form a heteroaryl or heterocyclyl, preferably a C3-10 heterocyclyl, wherein the heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl;
• R4 is selected from hydrogen or C1-6 alkyl;
• R5 is selected from the following groups:

A compound of formula (III) or a pharmaceutically acceptable salt thereof:

• Y is selected from C;
• X is selected from CH2, NH, and O;
• M and pyrimidine ring (Y═C) form a fused heteroaryl or heterocyclyl, wherein M is selected from a heteroaryl or heterocyclyl fused to a pyrimidine ring, preferably C5-C10 heteroaryl including pyrimidine ring, C4-C10 heterocyclyl;
• and the heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, oxo, halogen, or C1-6 haloalkyl;
• alternatively, when M does not form a fused heteroaryl or heterocyclyl with a pyrimidine ring (Y═C), then Y is selected from C—Cl and C—CF3;
• R1 is selected from the following groups:
• R3 is selected from hydrogen or C1-6 alkyl;
• or R2 and R3 together with the nitrogen atom to which they are attached form a heteroaryl or heterocyclyl, preferably a C3-10 heterocyclyl;
• wherein the heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl;
• R4 and R5 are selected from hydrogen, nitro, cyano, hydroxy, C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl or C1-6 haloalkoxy, alkylacyl, C1-6 alkylacyl, alkoxyacyl, C1-C6 alkoxyacyl, aminoacyl, or C1-6 alkylaminoacyl.

A compound of formula (V) or a pharmaceutically acceptable salt thereof

• wherein
• X is selected from C and N;
• R1, R2, R3, R4, and R5 are selected from hydrogen, nitro, cyano, hydroxy, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl or C1-6 haloalkoxy, alkylacyl, C1-6 alkylacyl, alkoxyacyl, C1-C6 alkoxyacyl, aminoacyl, or C1-6 alkylaminoacyl;
• n is selected from 1, 2, 3, and 4;
• R6 is selected from the following groups: